Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-051: Pembrolizumab in Pediatric Patients With Advanced Melanoma, Solid Tumors, or Lymphoma
NCT02332668Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2015
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, lymphoma, solid tumor, classical Hodgkin lymphoma (cHL), sponsored by Merck & Co.. Started Mar 2015; status: recruiting.
02
Drugs
03
Conditions
melanomalymphomasolid tumorclassical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02332668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332668.